Rodman & Renshaw downgraded shares of Alto Neuroscience (NYSE:ANRO – Free Report) from a buy rating to a neutral rating in a research note published on Wednesday morning, Marketbeat.com reports.
A number of other research analysts have also commented on ANRO. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Wedbush reaffirmed an “outperform” rating and set a $29.00 price target on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.40.
Check Out Our Latest Research Report on Alto Neuroscience
Alto Neuroscience Stock Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Sell-side analysts forecast that Alto Neuroscience will post -2.63 EPS for the current fiscal year.
Institutional Trading of Alto Neuroscience
Several large investors have recently modified their holdings of ANRO. Rhumbline Advisers bought a new stake in shares of Alto Neuroscience during the 2nd quarter worth approximately $113,000. Federated Hermes Inc. increased its stake in Alto Neuroscience by 33.3% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after acquiring an additional 3,000 shares during the last quarter. University of Texas Texas AM Investment Managment Co. acquired a new position in Alto Neuroscience during the first quarter valued at approximately $340,000. Bank of New York Mellon Corp bought a new stake in Alto Neuroscience during the second quarter worth $252,000. Finally, Bowie Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at $462,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
- Five stocks we like better than Alto Neuroscience
- 5 discounted opportunities for dividend growth investors
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Buy Cheap Stocks Step by Step
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Are Dividends? Buy the Best Dividend Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.